Jason Mast , 2025-04-22 21:36:00
A landmark new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of standard-of-care therapy, Bristol Myers Squibb announced Tuesday.
The drug, Cobenfy, was approved last year based on data from three randomized studies comparing the drug to placebo. It was the first new mechanism-of-action approved for schizophrenia in decades. Doctors and patients hope it can provide an alternative to generic antipsychotics, which can often curb key symptoms but come with significant side effects.
In the new trial, Bristol tested to see whether Cobenfy could also work in combination with a generic antipsychotic to provide more relief than one drug alone. The answer, at least in this study, was no.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
